[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"notifications-list":3,"$f2w66fhrpmo4k7":5},{"data":4},[],{"data":6,"error":10},{"id":7,"documentId":8,"slug":9,"name":9,"proprietary_name":10,"non_proprietary_name":10,"is_proprietary":10,"active_ingredient":10,"administration_route":10,"available_strength":10,"dosage_form":10,"dose_schedule":10,"drug_unit":10,"is_available_generically":10,"mechanism_of_action":10,"overdosage":10,"warning":10,"species":11,"citations":12,"dose_schedules":23,"available_strengths":70,"label_statements":103,"drug_classes":154,"specialties":165,"medical_conditions":166,"animal_species":167},1745,"wzfuxhz989frlpawxva7m3i3","methylprednisolone",null,[],[13,19],{"source":14,"licence":15,"source_url":16,"harvested_by":17,"retrieved_at":18},"FDA Green Book","US public domain","https:\u002F\u002Fanimaldrugsatfda.fda.gov\u002Fadafda\u002Fapp\u002Fsearch\u002Fpublic\u002FingredientsInformationExcel\u002FSection2ActiveIngredients","load-reference-corpus.cjs","2026-09-07",{"source":20,"licence":21,"source_url":22,"harvested_by":17,"retrieved_at":18},"UK VMD PID","OGL v3.0","https:\u002F\u002Fwww.vmd.defra.gov.uk\u002Fproductinformationdatabase\u002Fdownloads\u002Fvmd_productinformationdatabase.xlsx",[24,30,35,41,46,50,53,56,61,66],{"id":25,"dose_text":26,"species":27,"administration_route":28,"limitation":10,"source_label":29},12533,"Administer total daily dose orally in equally divided doses 6 to 10 hours apart until response is noted or 7 days have elapsed. When response is attained, dosage should be gradually reduced until maintenance level is achieved. Hazardous for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Systemic therapy with methylprednisolone is contraindicated in animals with arrested tuberculosis, peptic ulcer, acute psychoses, cushingoid syndrome. The presence of active tuberculosis, diabetes, osteoporosis, chronic psychotic reactions, predisposition to thrombophlebitis, hypertension, congestive heart failure or renal insufficiency necessitates carefully controlled use of corticosteroids. Some of these conditions occur only rarely in dogs and cats but should be kept in mind. Anti-inflammatory action of corticosteroids may mask signs of infection.","Dogs","Oral","Medrol® Tablets",{"id":31,"dose_text":32,"species":27,"administration_route":28,"limitation":33,"source_label":34},12534,"Administer total daily dose orally in equally divided doses 6 to 10 hours apart until response is noted or 7 days have elapsed. When response is attained, dosage should be gradually reduced until maintenance level is achieved.\n5 to 15 pounds: 2 milligrams;\n15 to 40 pounds: 2 to 4 milligrams;\n40 to 80 pounds: 4 to 8 milligrams.","Hazardous for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Systemic therapy with methylprednisolone is contraindicated in animals with arrested tuberculosis, peptic ulcer, acute psychoses, cushingoid syndrome. The presence of active tuberculosis diabetes, osteoporosis, chronic psychotic reactions, predisposition to thrombophlebitis, hypertension, congestive heart failure or renal insufficiency necessitates carefully controlled use of corticosteroids. Some of these conditions occur only rarely but should be kept in mind. Anti-inflammatory action of corticosteroids may mask signs of infection.","Methylprednisolene Tablets",{"id":36,"dose_text":37,"species":27,"administration_route":38,"limitation":39,"source_label":40},12535,"2 to 40 milligrams (up to 120 milligrams in extremely large breeds or dogs with severe involvement) intramuscularly. Dosage may be repeated when necessary. Or up to 20 milligrams intrasynovially. Dosage may be repeated when necessary.","Intramuscular, Intrasynovial","Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis, peptic ulcer, and Cushing's syndrome. The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal insufficiency, predisposition to thrombophlebitis hypertension, or congestive heart failure necessitates carefully controlled use of corticosteroids. Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contraindicated in the presence of acute infectious conditions. Exacerbation of pain, further loss of joint motion, with fever and malaise following injection may indicate that the condition has become septic. Appropriate antibacterial therapy should be instituted immediately.","Methylprednisolone Acetate Inj.",{"id":42,"dose_text":43,"species":27,"administration_route":28,"limitation":44,"source_label":45},12536,"Dogs under 15 pounds, 1\u002F4 to 1 tablet daily;\n15 to 60 pounds, 1 to 2 tablets daily;\n60 pounds and over, 2 tablets daily.","Administer total daily dose in divided doses 6 to 10 hours apart, with a light feeding. When response is attained, dosage should be gradually reduced until maintenance level is achieved. Do not administer to cats. Do not overdose. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Systemic therapy with methylprednisolone is contraindicated in animals with tuberculosis, chronic nephritis, peptic ulcer, or Cushingoid syndrome. The presence of diabetes mellitus, osteoporosis predisposition to thrombophlebitis, hypertension, congestive heart failure, or renal insufficiency necessitates carefully controlled use of corticosteroids. Anti-inflammatory action of corticosteroids may mask signs of infection.","Cortaba® Tablets",{"id":47,"dose_text":32,"species":48,"administration_route":28,"limitation":49,"source_label":34},12537,"Cats","Hazardous for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Systemic therapy with methylprednisolone is contraindicated in animals with arrested tuberculosis, peptic ulcer, acute psychoses, corneal ulcer, and cushingoid syndrome. The presence of diabetes, osteoporosis, chronic psychotic reactions, predisposition to thrombophlebitis, hypertension, congestive heart failure, renal insufficiency and active tuberculosis necessitates carefully controlled use. Some of the above conditions occur only rarely in dogs and cats but should be kept in mind. Antiinflammatory action of corticosteroids may mask signs of infection.",{"id":51,"dose_text":52,"species":48,"administration_route":28,"limitation":26,"source_label":29},12538,"5 to 15 pounds, 2 milligrams;\n15 to 40 pounds, 2 to 4 milligrams;\n40 to 80 pounds, 4 to 8 milligrams.",{"id":54,"dose_text":55,"species":48,"administration_route":38,"limitation":39,"source_label":40},12539,"10 to 20 milligrams intramuscularly. Dosage may be repeated when necessary.",{"id":57,"dose_text":58,"species":59,"administration_route":38,"limitation":60,"source_label":40},12540,"200 milligrams intramuscularly. Dosage may be repeated when necessary. Or 40 to 240 milligrams intrasynovially. Dosage may be repeated when necessary.","Horses","Not for use in horses intended for food. Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis, peptic ulcer, and Cushing's syndrome. The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal insufficiency, predisposition to thrombophlebitis hypertension, or congestive heart failure necessitates carefully controlled use of corticosteroids. Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contraindicated in the presence of acute infectious conditions. Exacerbation of pain, further loss of joint motion, with fever and malaise following injection may indicate that the condition has become septic. Appropriate antibacterial therapy should be instituted immediately.",{"id":62,"dose_text":63,"species":10,"administration_route":64,"limitation":10,"source_label":65},12541,"The keystone of satisfactory therapeutic management with MEDROL Tablets, as with its steroid predecessors, is individualization of dosage in reference to the severity of the disease, the anticipated duration of steroid therapy, and the animal patient's threshold or tolerance for steroid excess.\nThe prime objective of steroid therapy should be to achieve a satisfactory degree of control with a minimum effective daily dose.\nThe dosage recommendations are suggested\naverage total daily doses\nand are intended as guides. As with other orally administered corticosteroids, the total daily dose of MEDROL should be given in equally divided doses. The initial suppressive dose level is continued until a satisfactory clinical response is obtained, a period usually of 2 to 7 days in the case of musculoskeletal diseases, allergic conditions affecting the skin or respiratory tract, and ocular inflammatory diseases. If a satisfactory response is not obtained in 7 days, reevaluation of the case to confirm the original diagnosis should be made. As soon as a satisfactory clinical response is obtained, the daily dose should be reduced gradually, either to termination of treatment in the case of acute conditions (eg, seasonal asthma, dermatitis, acute ocular inflammations) or to the minimal effective maintenance dose level in the case of chronic conditions (eg, rheumatoid arthritis). In chronic conditions, and in rheumatoid arthritis especially, it is important that the reduction in dosage from initial to maintenance dose levels be accomplished slowly. The maintenance dose level should be adjusted from time to time as required by fluctuation in the activity of the disease and the animal's general status. Accumulated experience has shown that the long-term benefits to be gained from continued steroid maintenance are probably greater the lower the maintenance dose level. In rheumatoid arthritis in particular, maintenance steroid therapy should be at the lowest possible level.\nImportant:\nIn the therapeutic management of animal patients with chronic diseases such as rheumatoid arthritis, methylprednisolone should be regarded as a highly valuable adjunct, to be used in conjunction with but not as replacement for standard therapeutic measures.\nAverage total daily oral doses for dogs and cats:\n5 to 15 lb body wt\n2 mg\n15 to 40 lb body wt\n2 to 4 mg\n40 to 80 lb body wt\n4 to 8 mg\nThe total daily dose should be given in divided doses, 6 to 10 hours apart.","ORAL","Medrol®",{"id":67,"dose_text":68,"species":10,"administration_route":64,"limitation":10,"source_label":69},12542,"The keystone of satisfactory therapeutic management with methylprednisolone, as with its steroid predecessors, is individualization of dosage in reference to the severity of the disease, the anticipated duration of steroid therapy and the animal’s threshold or tolerance for steroid excess. The prime objective of steroid therapy should be achieve a satisfactory degree of control with a minimum effective daily dose.\nThe dosage recommendations are suggested average total daily doses and are intended as guides. As with other orally administered corticosteroids, the total daily dose of methylprednisolone tablets should be given in equally divided doses. The initial suppressive dose level is continued until a satisfactory clinical response is obtained, a period usually of 2 to 7 days in the case of musculoskeletal diseases, allergic conditions affecting the skin or respiratory tract and ocular inflammatory diseases. If a satisfactory response is not obtained in 7 days, re-evaluation of the case to confirm the original diagnosis should be made. As soon as a satisfactory clinical response is obtained, the daily dose should be reduced gradually, either to termination of treatment in the case of acute conditions (e.g., seasonal asthma, dermatitis, acute ocular inflammations) or to the minimal effective maintenance dose level in the case of chronic conditions (e.g., rheumatoid arthritis). In chronic conditions, and in rheumatoid arthritis especially, it is important that the reduction in dosage from initial to maintenance dose levels be accomplished slowly. The maintenance dose level should be adjusted from time to time as required by fluctuation in the activity of the disease and the animal’s general status. Accumulated experience has shown that the long-term benefits to be gained from continued steroid maintenance are probably greater the lower the maintenance dose level. In rheumatoid arthritis in particular, maintenance steroid therapy should be at the lowest possible level.","Methylprednisolone Tablets, USP For Oral Use in Dogs and Cats OnlyCAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.",[71,75,77,79,83,85,88,91,93,95,98,100],{"id":72,"strength_text":73,"dosage_form":74,"proprietary_name":40,"species":27,"source_label":40},10826,"Each milliliter of aqueous suspension contains 20 or 40 milligrams of methylprednisolone acetate.","Liquid (Suspension)",{"id":76,"strength_text":73,"dosage_form":74,"proprietary_name":40,"species":48,"source_label":40},10827,{"id":78,"strength_text":73,"dosage_form":74,"proprietary_name":40,"species":59,"source_label":40},10828,{"id":80,"strength_text":81,"dosage_form":82,"proprietary_name":29,"species":27,"source_label":29},10829,"Each tablet contains 1 or 4 milligrams of methylprednisolone.","Tablet",{"id":84,"strength_text":81,"dosage_form":82,"proprietary_name":29,"species":48,"source_label":29},10830,{"id":86,"strength_text":87,"dosage_form":82,"proprietary_name":45,"species":27,"source_label":45},10831,"Each tablet contains 0.5 milligram of methylprednisolone and 300 milligrams of aspirin.",{"id":89,"strength_text":73,"dosage_form":74,"proprietary_name":90,"species":27,"source_label":90},10832,"Depo-Medrol®",{"id":92,"strength_text":73,"dosage_form":74,"proprietary_name":90,"species":48,"source_label":90},10833,{"id":94,"strength_text":73,"dosage_form":74,"proprietary_name":90,"species":59,"source_label":90},10834,{"id":96,"strength_text":97,"dosage_form":82,"proprietary_name":34,"species":27,"source_label":34},10835,"Each tablet contains 1, 2 or 4 milligrams of methylprednisolone.",{"id":99,"strength_text":97,"dosage_form":82,"proprietary_name":34,"species":48,"source_label":34},10836,{"id":101,"strength_text":102,"dosage_form":10,"proprietary_name":10,"species":10,"source_label":65},10837,"4 mg \u002F 1 1",[104,109,112,115,118,121,124,127,130,134,137,141,144,147,151],{"id":105,"kind":106,"statement":107,"species":27,"limitation":108,"source_label":90},18337,"indication","Treatment of inflammation and related disorders in dogs; treatment of allergic and dermatologic disorders in dogs; and as supportive therapy to antibacterial treatment of severe infections in dogs.","Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis, peptic ulcer, and Cushing's syndrome. The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal insufficiency, predisposition to thrombophlebitis, hypertension, or congestive heart failure necessitates carefully controlled use of corticosteroids. Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contraindicated in the presence of acute infectious conditions. Exacerbation of pain, further loss of joint motion, with fever and malaise following injection may indicate that the condition has become septic. Appropriate antibacterial therapy should be instituted immediately.",{"id":110,"kind":106,"statement":111,"species":27,"limitation":44,"source_label":45},18338,"As an anti-inflammatory and analgesic agent in dogs.",{"id":113,"kind":106,"statement":114,"species":27,"limitation":10,"source_label":29},18339,"For use in dogs as an anti-inflammatory agent.",{"id":116,"kind":106,"statement":117,"species":48,"limitation":108,"source_label":90},18340,"Treatment of inflammation and related disorders in cats; treatment of allergic and dermatologic disorders in cats; and as supportive therapy to antibacterial treatment of severe infections in cats.",{"id":119,"kind":106,"statement":120,"species":48,"limitation":26,"source_label":29},18341,"For use in cats as an anti-inflammatory agent.",{"id":122,"kind":106,"statement":123,"species":59,"limitation":108,"source_label":90},18342,"Treatment of inflammation and related disorders in horses.",{"id":125,"kind":106,"statement":126,"species":10,"limitation":10,"source_label":65},18343,"The indications for MEDROL Tablets are the same as those for other anti-inflammatory steroids and comprise the various collagen, dermal, allergic, ocular, otic, and musculoskeletal conditions known to be responsive to the anti-inflammatory corticosteroids. Representative of the conditions in which the use of steroid therapy and the benefits to be derived therefrom have had repeated confirmation in the veterinary literature are: (1) dermal conditions, such as non-specific eczema, summer dermatitis, and burns; (2) allergic manifestations, such as acute urticaria, allergic dermatitis, drug and serum reactions, bronchial asthma, and pollen sensitivities; (3) ocular conditions, such as iritis, iridocyclitis, secondary glaucoma, uveitis, and chorioretinitis; (4) otic conditions, such as otitis externa; (5) musculoskeletal conditions, such as myositis, rheumatoid arthritis, osteoarthritis, and bursitis; (6) various chronic or recurrent diseases of unknown etiology such as ulcerative colitis and nephrosis.\nIn acute adrenal insufficiency, MEDROL may be effective because of its ability to correct the defect in carbohydrate metabolism and relieve the impaired diuretic response to water characteristic of primary or secondary adrenal insufficiency. However, because this agent lacks significant mineralocorticoid activity, the parent hormones, SOLU-CORTEF® containing hydrocortisone sodium succinate, CORTEF® containing hydrocortisone, or cortisone should be used when salt retention is indicated.",{"id":128,"kind":106,"statement":129,"species":10,"limitation":10,"source_label":69},18344,"The indications are the same as those for other anti-inflammatory steroids and comprise the various collagen, dermal, allergic, ocular, otic and musculoskeletal conditions known to be responsive to the anti-inflammatory corticosteroids. Representative of the conditions in which the use of steroid therapy and the benefits to be derived therefrom have had repeated confirmation in the veterinary literature are:\nDermal conditions, such as non-specific eczema and summer dermatics. 1,2,4\nAllergic manifestations, such as acute urticaria, allergic dermatitis, drug and serum reactions, non-specific pruritus, bronchial asthma and pollen sensitivities. 1,2,3,4,5\nOcular Conditions, such as iritis, iridocyclitis, secondary glaucoma, uveitis and chlorioretinitis. 1,3,4,5\nOtic Conditions, such as otitis externa. 4\nMusculoskeletal Conditions, such as myositis, rheumatoid arthritis, osteoarthritis and bursitis. 1,2,3,4,5\nVarious chronic or recurrent diseases of unknown etiology such as ulcerative colitis and nephrosis. 1,2,3,5\nIn acute adrenal insufficiency, methylprednisolone may be effective because of its ability to correct the defect in carbohydrate metabolism and relieve the impaired diuretic response to water, characteristic of primary or secondary adrenal insufficiency. However, because this agent lacks significant mineralocorticoid activity, hydrocortisone sodium succinate or cortisone should be used when salt retention is indicated.",{"id":131,"kind":132,"statement":133,"species":10,"limitation":10,"source_label":90},18345,"contraindication","Systemic therapy with methylprednisolone acetate, as with other corticoids, is\ncontraindicated in animals with arrested tuberculosis, peptic ulcer, and Cushing’s\nsyndrome. The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal\ninsufficiency, predisposition to thrombophlebitis, hypertension, or congestive heart\nfailure necessitates carefully controlled use of corticosteroids. Intrasynovial,\nintratendinous, or other injections of corticosteroids for local effect are contraindicated\nin the presence of acute infectious conditions. Exacerbation of pain, further loss of\njoint motion, with fever and malaise following injection may indicate that the condition\nhas become septic. Appropriate antibacterial therapy should be instituted immediately.",{"id":135,"kind":132,"statement":136,"species":10,"limitation":10,"source_label":69},18346,"Do not use in viral infections. Methylprednisolone, like prednisolone, is contraindicated in animals with arrested tuberculosis, peptic ulcer, acute psychoses, corneal ulcer and Cushingoid syndrome. The presence of diabetes, osteoporosis, chronic psychotic reactions, predisposition to thrombophlebitis, hypertension, congestive heart failure, renal insufficiency and active tuberculosis necessitates carefully controlled use. Some of the above conditions occur only rarely in dogs and cats but should be kept in mind.",{"id":138,"kind":139,"statement":140,"species":10,"limitation":10,"source_label":69},18347,"warning","Because of its inhibitory effect on fibroplasia, methylprednisolone may mask the signs of infection and enhance dissemination of the infecting organism. Hence all animals receiving methylprednisolone should be watched for evidence of intercurrent infection. Should infection occur, it must be brought under control by use of appropriate antibacterial measures or administration of methylprednisolone should be discontinued.\nNot for human use. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis.\nAdditionally, corticosteroid administered to dogs, rabbits and rodents during pregnancy have produced cleft palate. Other congenital anomalies including deformed forelegs, phocomella and anasarca have been reported in offspring of dogs which received corticosteroids during pregnancy.",{"id":142,"kind":139,"statement":143,"species":10,"limitation":10,"source_label":90},18348,"Clinical and experimental data have demonstrated that corticosteroids administered\norally or parenterally to animals may induce the first stage of parturition when administered\nduring the last trimester of pregnancy and may precipitate premature\nparturition followed by dystocia, fetal death, retained placenta and metritis.\nAdditionally, corticosteroids administered to dogs, rabbits, and rodents during\npregnancy have resulted in cleft palate in offspring. Corticosteroids administered to\ndogs during pregnancy have also resulted in other congenital anomalies, including\ndeformed forelegs, phocomelia, and anasarca.\nNot for human use. Do not use in horses intended for human consumption.",{"id":145,"kind":139,"statement":146,"species":10,"limitation":10,"source_label":65},18349,"Medrol®\n(methylprednisolone tablets)\nFor Oral Use in Dogs and Cats\nCaution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.",{"id":148,"kind":149,"statement":150,"species":10,"limitation":10,"source_label":65},18350,"adverse_reaction","With therapeutically equivalent doses, the likelihood of occurrence of troublesome side effects is less with methylprednisolone than with prednisolone; moreover, side effects actually have been conspicuously absent during clinical trials with MEDROL Tablets in dogs and cats. However, methylprednisolone is similar to prednisolone in regard to kinds of side effects and metabolic alterations to be anticipated when treatment is intensive or prolonged. In animal patients with diabetes mellitus, use of methylprednisolone may be associated with an increase in the insulin requirement. Negative nitrogen balance may occur, particularly in animals that require protracted maintenance therapy; measures to counteract persistent nitrogen loss include a high protein intake and the administration when indicated, of a suitable anabolic agent. Excessive loss of potassium, like excessive retention of sodium, is not likely to be induced by effective maintenance doses of MEDROL. However, these effects should be kept in mind and the usual regulatory measures employed as indicated. Ecchymotic manifestations, while not noted during the clinical evaluation in dogs and cats, may occur. If such reactions do occur and are serious, reduction in dosage or discontinuance of methylprednisolone therapy may be indicated. Concurrent use of daily oral supplements of ascorbic acid may be of value in helping to control ecchymotic tendencies.\nSince methylprednisolone, like prednisolone, suppresses endogenous adrenocortical activity, it is highly important that the animal patient receiving MEDROL be under careful observation, not only during the course of treatment but for some time after treatment is terminated. Adequate adrenocortical supportive therapy with cortisone or hydrocortisone, and including ACTH, must be employed promptly if the animal is subjected to any unusual stress such as surgery, trauma, or severe infection.",{"id":152,"kind":149,"statement":153,"species":10,"limitation":10,"source_label":69},18351,"Methylprednisolone is similar to prednisolone in regard to kinds of side effects and metabolic alterations to be anticipated when treatment is intensive or prolonged. In animals with diabetes mellitus, use of methylprednisolone may be associated with an increase in the insulin requirement. Negative nitrogen balance may occur, particularly in animals that require protracted maintenance therapy; measures to counteract persistent nitrogen loss include a high protein intake and the administration, when indicated, of a suitable anabolic agent. Excessive loss of potassium, like excessive retention of sodium, is not likely to be induced by effective maintenance doses of methylprednisolone. However these effects should be kept in mind and the usual regulatory measures employed as indicated. Ecchymotic manifestations, while not noted during the clinical evaluation in dogs and cats, may occur. If such reactions do occur and are serious, reduction in dosage or discontinuance of methylprednisolone therapy may be indicated. Concurrent use of daily oral supplements of ascorbic acid may be of value in helping to control ecchymotic tendencies.\nSide effects, such as SAP and SGPT enzyme elevations, weight loss, anorexia, polydipsia and polyuria have occurred following the use of synthetic corticosteroids in dogs. Vomiting and diarrhea (occasionally bloody) have been observed in dogs and cats. Cushing’s syndrome in dogs has been reported in association with prolonged or repeated steroid therapy.\nTo report suspected adverse drug events, for technical assistance or to obtain a copy of the Safety Data Sheet, contact Cronus Pharma LLC at 1-844-227-6687 and 1-844-2-CRONUS. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or http:\u002F\u002Fwww.fda.gov\u002Freportanimalae.",[155,160],{"id":156,"documentId":157,"slug":158,"name":159},822,"w6ha1c9jm6bdr9mrj7mg5l95","glucocorticoid-receptor-agonists","Glucocorticoid Receptor Agonists",{"id":161,"documentId":162,"slug":163,"name":164},856,"dcdetq8zlaxge6js44km7uqm","corticosteroid-hormone-receptor-agonists","Corticosteroid Hormone Receptor Agonists",[],[],[]]